K-756,130017-40-2

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

K-756

CAS No. : 130017-40-2

MCE 国际站：K-756

产品活性：K-756 是一种直接的选择性 tankyrase (TNKS) 抑制剂，抑制 TNKS1 和 TNKS2 的 ADP-核糖基化活性，IC₅₀ 分别为 31 和 36 nM。

研究领域：Cell Cycle/DNA Damage  |  Epigenetics

作用靶点：PARP

In Vitro: K-756 is a novel and selective Wnt/β-catenin pathway inhibitor targeting tankyrase (TNKS). TNKS is one of the members of the PARP family (it is also known as PARP5). K-756 binds to the induced pocket of TNKS and inhibits its enzyme activity. To study the isoform selectivity of K-756, the PARP family enzyme inhibitory activity at 10 μM is evaluated. K-756 inhibits TNKS1 and TNKS2 by 97% and 100%, respectively. In contrast, the inhibitory activity of K-756 against PARP1, PARP2, PARP3, PARP6, PARP7, and PARP11 is less than 13%. K-756 inhibits the cell growth of APC-mutant colorectal cancer COLO 320DM and SW403 cells by inhibiting the Wnt/β-catenin pathway. K-756 strongly inhibits the reporter activity in DLD-1/TCF-Luc cells with an IC₅₀ of 110 nM, but does not inhibit DLD-1/mtTCF-Luc cells, even at 1,000 nM. APC-mutant colorectal cancer cell line COLO 320DM and SW403 cells are treated with K-756 and after 144 hours, cell growth inhibition is measured by an XTT assay. The application of K-756 inhibits the cell growth of COLO 320DM with a GI₅₀ of 780 nM. K-756 also inhibits SW403 with a GI₅₀ of 270 nM.

In Vivo: DLD-1/TCF-Luc cell xenografts are created in SCID mice. Vehicle (0.5% MC400) or K-756 is administered orally once a day for 3 days at 100, 200, and 400 mg/kg. The Wnt/β-catenin signal inhibition in the tumor is detected by measuring FGF20 and LGR5 and luciferase activity. The expression of FGF20 and reporter activity are significantly decreased at doses of 100 mg/kg and above at 3-day administration. The expression of LGR5 is significantly decreased at doses of 200 mg/kg and above at 3-day administration. The maximum inhibitory activity is reached with the administration of K-756 at a dose of 400 mg/kg at 3-day administration. The Wnt/β-catenin signal inhibition at a dose of 400 mg/kg is observed from 1-day administration.

相关产品：Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  Anti-Cancer Compound Library  |  Anti-Aging Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Heterocyclic Compound Library  |  Highly Selective Inhibitors Library  |  Olaparib  |  XAV-939  |  Talazoparib  |  Niraparib  |  Saruparib  |  Rucaparib  |  Veliparib  |  PJ34  |  Chlorin e6  |  Pamiparib  |  RBN-2397  |  Fucosterol  |  Dehydrocorydaline  |  Fluzoparib  |  G007-LK  |  RBN012759  |  3-Aminobenzamide  |  AG14361  |  Patritumab  |  Daphnetin  |  NVP-TNKS656  |  Rucaparib monocamsylate  |  AZD-2461  |  EB-47 dihydrochloride  |  Iniparib

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds